Management of hyperthyroidism in children

References

• Grüters A. Ocular manifestations in children and adolescents with thyrotoxicosis. Exp Clin Endocrinol Diabetes. 1999;107(Suppl 5):S172–S174.
   PubMed Web of Science ®Google Scholar
• Cappa M, Bizzarri C, Crea F. Autoimmune thyroid diseases in children. J Thyroid Res. 2011;675703. doi:10.4061/2011/675703.
   Google Scholar
• Wong GW, Lai J, Cheng PS. Growth in childhood thyrotoxicosis. Eur J Pediatr. 1999;158:776–779.
   PubMed Web of Science ®Google Scholar
• Rivkees SA. Treatment of hyperthyroidism due to Graves’ disease in children. In: Krassas GE, Rivkees SA, Kiess W, (editors. Disease of the thyroid in childhood and adolescence. Pediatr Adolesc Med. Vol 11. Basel: Karger; 2007. p. 169–191.
   Google Scholar
• Williamson S, Greene SA. Incidence of thyrotoxicosis in childhood: a national population based study in the UK and Ireland. Clin Endocrinol. 2010;72:358–363.
   PubMed Web of Science ®Google Scholar
• Léger J. Graves’ disease in children. In: Szinnai G, editor. Paediatric thyroidology. Endocr Dev. Vol. 26. Basel: Karger; 2014. p. 171–182.
   Google Scholar
• Abraham-Nordling M, Byström K, Törring O, et al. Incidence of hyperthyroidism in Sweden. Eur J Endocrinol. 2011;165:899–905.
   PubMed Web of Science ®Google Scholar
• Michels AW, Eisenbarth GS. Immunologic endocrine disorders. J Allergy Clin Immunol. 2010;125(Suppl 2):S226–S237.
   PubMed Web of Science ®Google Scholar
• Livadas S, Xekouki P, Fouka F, et al. Prevalence of thyroid dysfunction in Turner’s syndrome: a long-term follow-up study and brief literature review. Thyroid. 2005;15:1061–1066.
   PubMed Web of Science ®Google Scholar
• Fukuda I, Hizuka N, Kurimoto M, et al. Autoimmune thyroid diseases in 65 Japanese women with Turner syndrome. Endocr J. 2009;56:983–986.
   PubMed Web of Science ®Google Scholar
• Wasniewska M, Corrias A, Messina MF, et al. Graves’ disease prevalence in a young population with Turner syndrome. J Endocrinol Invest. 2010;33:69–70.
   PubMed Web of Science ®Google Scholar
• Gawlik A, Gawlik T, Januszek-Trzciakowska A, et al. Incidence and dynamics of thyroid dysfunction and thyroid autoimmunity in girls with Turner’s syndrome: a long-term follow-up study. Horm Res Paediatr. 2011;76:314–320.
   PubMed Web of Science ®Google Scholar
• Bakalov VK, Gutin L, Cheng CM, et al. Autoimmune disorders in women with Turner syndrome and women with karyotypically normal primary ovarian insufficiency. J Autoimmun. 2012;38:315–321.
   PubMed Web of Science ®Google Scholar
• Valenzise M, Aversa T, Corrias A, et al. Epidemiology, presentation and long-term evolution of Graves’ disease in children, adolescents and young adults with Turner syndrome. Horm Res Paediatr. 2014;81:245–250.
   PubMed Web of Science ®Google Scholar
• Goday-Arno A, Cerda-Esteva M, Flores-Le-Roux JA, et al. Hyperthyroidism in a population with Down syndrome (DS). Clin Endocrinol. 2009;71:110–114.
   PubMed Web of Science ®Google Scholar
• De Luca F, Corrias A, Salerno M, et al. Peculiarities of Graves’ disease in children and adolescents with Down’s syndrome. Eur J Endocrinol. 2010;162:591–595.
   PubMed Web of Science ®Google Scholar
• Hemminki K, Li X, Sundquist J, et al. The epidemiology of Graves’ disease: evidence of a genetic and an environmental contribution. J Autoimmun. 2010;34:J307–J313.
   PubMed Web of Science ®Google Scholar
• Birrell G, Cheetham T. Juvenile thyrotoxicosis; can we do better? Arch Dis Child. 2004;89:745–750.
   PubMed Web of Science ®Google Scholar
• Lee JA, Grumbach MM, Clark OH. The optimal treatment for pediatric Graves’ disease is surgery. J Clin Endocrinol Metab. 2007;92:801–803.
   PubMed Web of Science ®Google Scholar
• Rivkees SA, Dinauer C. An optimal treatment for pediatric Graves’ disease is radioiodine. J Clin Endocrinol Metab. 2007;92:797–800.
   PubMed Web of Science ®Google Scholar
• Kaguelidou F, Carel JC, Leger J. Graves’ disease in childhood: advances in management with antithyroid drug therapy. Horm Res. 2009;71:310–317.
   PubMed Web of Science ®Google Scholar
• Rivkees SA. Pediatric Graves’ disease: controversies in management. Horm Res Paediatr. 2010;74:305–311.
   PubMed Web of Science ®Google Scholar
• Schenk D, Donaldson M, Cheetham T. Which antithyroid drug regimen in paediatric Graves’ disease? Clin Endocrinol. 2012;77:806–807.
   PubMed Web of Science ®Google Scholar
• Léger J, Kaguelidou F, Alberti C, et al. Graves’ disease in children. Best Pract Res Clin Endocrinol Metab. 2014 Mar;28:233–243.
   PubMed Web of Science ®Google Scholar
• Cooper DS. Antithyroid drugs for the treatment of hyperthyroidism caused by Graves’ disease. Endocrinol Metab Clin North Am. 1998;27:225–247.
   PubMed Web of Science ®Google Scholar
• Rivkees SA, Mattison DR. Ending propylthiouracil-induced liver failure in children. N Engl J Med. 2009;360:1574–1575.
   PubMed Web of Science ®Google Scholar
• Rivkees SA, Szarfman A. Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children. J Clin Endocrinol Metab. 2010;95:3260–3267.
   PubMed Web of Science ®Google Scholar
• Radetti G, Baronio F. Hyperthyroidism. In: Bona G, De Luca F, Monzoni A, editors. Thyroid diseases in childhood: recent advances from basic science to clinical practice. Basel (Switzerland): Springer; 2015. p. 203–216.
   Google Scholar
• Rivkees SA, Stephenson K, Dinauer C. Adverse events associated with methimazole therapy of Graves’ disease in children. Int J Pediatr Endocrinol. 2010;2010:176970.
   PubMedGoogle Scholar
• Hashizume K, Ichikawa K, Sakurai A, et al. Administration of thyroxine in treated Graves’ disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N Engl J Med. 1991;324:947–953.
   PubMed Web of Science ®Google Scholar
• Ladenson PW. Treatments for Graves’ disease – letting the thyroid rest. N Engl J Med. 1991;324:989–990.
   PubMed Web of Science ®Google Scholar
• Abraham P, Avenell A, McGeoch SC, et al. Antithyroid drug regimen for treating Graves’ hyperthyroidism. Cochrane Database Syst Rev. 2010;1:CD003420 .
   PubMed Web of Science ®Google Scholar
• Vaidya B, Wright A, Shuttleworth J, et al. Block & replace regime versus titration regime of antithyroid drugs for the treatment of Graves’ disease: a retrospective observational study. Clin Endocrinol. 2014;81:610–613.
   PubMed Web of Science ®Google Scholar
• Bahn RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract. 2011;17:456–520.
   PubMed Web of Science ®Google Scholar
• Glaser NS, Styne DM. Predictors of early remission of hyperthyroidism in children. J Clin Endocrinol Metab. 1997;82:1719–1726.
   PubMed Web of Science ®Google Scholar
• Lazar L, Kalter-Leibovici O, Pertzelan A, et al. Thyrotoxicosis in prepubertal children compared with pubertal and postpubertal patients. J Clin Endocrinol Metab. 2000;85:3678–3682.
   PubMed Web of Science ®Google Scholar
• Weetman AP. Graves’ hyperthyroidism: how long should antithyroid drug therapy be continued to achieve remission? Nat Clin Pract Endocrinol Metab. 2006;2:2–3.
   PubMedGoogle Scholar
• Shulman DI, Muhar I, Jorgensen EV, et al. Autoimmune hyperthyroidism in prepubertal children and adolescents: comparison of clinical and biochemical features at diagnosis and responses to medical therapy. Thyroid. 1997;7:755–760.
   PubMed Web of Science ®Google Scholar
• Read CH, Tansey MJ, Menda Y. A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves’ patients. J Clin Endocrinol Metab. 2004;89:4229–4233.
   PubMed Web of Science ®Google Scholar
• Kaguelidou F, Alberti C, Castanet M, et al. Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J Clin Endocrinol Metab. 2008;93:3817–3826.
   PubMed Web of Science ®Google Scholar
• Léger J, Gelwane G, Kaguelidou F, et al. Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves’ disease: national long-term cohort study. J Clin Endocrinol Metab. 2012;97:110–119 .
   PubMed Web of Science ®Google Scholar
• Léger J, Carel JC. Hyperthyroidism in childhood: causes, when and how to treat. J Clin Res Pediatr Endocrinol. 2013;5(Suppl 1):50–56.
   PubMed Web of Science ®Google Scholar
• Gastaldi R, Poggi E, Mussa A, et al. Graves’ disease in children: thyroid-stimulating hormone receptor antibodies as remission markers. J Pediatr. 2014;164:1189–1194.e1.
   PubMed Web of Science ®Google Scholar
• Lal G, Ituarte P, Kebebew E, et al. Should total thyroidectomy become the preferred procedure for surgical management of Graves’ disease? Thyroid. 2005;15:569–574.
   PubMed Web of Science ®Google Scholar
• Terris DJ, Gourin CG, Chin E. Minimally invasive thyroidectomy: basic and advanced techniques. Laryngoscope. 2006;116:350–356.
   PubMed Web of Science ®Google Scholar
• Sosa JA, Tuggle CT, Wang TS, et al. Clinical and economic outcomes of thyroid and parathyroid surgery in children. J Clin Endocrinol Metab. 2008;93:3058–3065.
   PubMed Web of Science ®Google Scholar
• Levy WJ, Schumacher OP, Gupta M. Treatment of childhood Graves’ disease: a review with emphasis on radioiodine treatment. Cleve Clin J Med. 1988;55:373–382.
   PubMed Web of Science ®Google Scholar
• Boice JD. Thyroid disease 60 years after Hiroshima and 20 years after Chernobyl. JAMA. 2006;295:1060–1062.
   PubMed Web of Science ®Google Scholar
• Rivkees SA, Sklar C, Freemark M. Clinical review 99: the management of Graves’ disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol Metab. 1998;83:3767–3776.
   PubMed Web of Science ®Google Scholar
• Bahn Chair RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011;21:593–646.
   PubMed Web of Science ®Google Scholar
• Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves’ disease. J Clin Endocrinol Metab. 2012;97:4549–4558.
   PubMed Web of Science ®Google Scholar
• Wong J, Wiseman SM. Thyroid surgery for treatment of Graves’ disease complicated by ophthalmopathy: a comprehensive review. Expert Rev Endocrinol Metab. 2015;10:327–336.
   PubMed Web of Science ®Google Scholar
• De Luca F, Santucci S, Corica D, et al. Hashimoto’s thyroiditis in childhood: presentation modes and evolution over time. Ital J Pediatr. 2013;39:8.
   PubMed Web of Science ®Google Scholar
• Aversa T, Lombardo F, Corrias A, et al. In young patients with Turner or Down syndrome, Graves’ disease presentation is often preceded by Hashimoto’s thyroiditis. Thyroid. 2014;24:744–747.
   PubMed Web of Science ®Google Scholar
• Aversa T, Messina MF, Mazzanti L, et al. The association with Turner syndrome significantly affects the course of Hashimoto’s thyroiditis in children, irrespective of karyotype. Endocrine. 2015;50:777–782.
   PubMed Web of Science ®Google Scholar
• Aversa T, Lombardo F, Valenzise M, et al. Peculiarities of autoimmune thyroid diseases in children with Turner or Down syndrome: an overview. Ital J Pediatr. 2015;41:39.
   PubMed Web of Science ®Google Scholar
• Aversa T, Salerno M, Radetti G, et al. Peculiarities of presentation and evolution over time of Hashimoto’s thyroiditis in children and adolescents with Down’s syndrome. Hormones (Athens). 2015;14:410–416.
   PubMedGoogle Scholar
• Aversa T, Valenzise M, Salerno M, et al. Metamorphic thyroid autoimmunity in Down syndrome: from Hashimoto’s thyroiditis to Graves’ disease and beyond. Ital J Pediatr. 2015;41:87.
   PubMed Web of Science ®Google Scholar
• Polak M, Le Gac I, Vuillard E, et al. Fetal and neonatal thyroid function in relation to maternal Graves’ disease. Best Pract Res Clin Endocrinol Metab. 2004;18:289–302.
   PubMed Web of Science ®Google Scholar
• Polak M, Leger J, Luton D, et al. Fetal cord blood sampling in the diagnosis and the treatment of fetal hyperthyroidism in the offsprings of a euthyroid mother, producing thyroid stimulating immunoglobulins. Ann Endocrinol. 1997;58:338–342.
   PubMed Web of Science ®Google Scholar
• Volumenie JL, Polak M, Guibourdenche J, et al. Management of fetal thyroid goiters: a report of 11 cases in a single perinatal unit. Prenat Diagn. 2000;20:799–806.
   PubMed Web of Science ®Google Scholar
• Singh PK, Parvin CA, Gronowski AM. Establishment of reference intervals for markers of fetal thyroid status in amniotic fluid. J Clin Endocrinol Metab. 2003;88:4175–4179.
   PubMed Web of Science ®Google Scholar
• Luton D, Le Gac I, Vuillard E, et al. Management of Graves’ disease during pregnancy: the key role of fetal thyroid gland monitoring. J Clin Endocrinol Metab. 2005;90:6093–6098.
   PubMed Web of Science ®Google Scholar
• Foulds N, Walpole I, Elmslie F, et al. Carbimazole embryopathy: an emerging phenotype. Am J Med Genet A. 2005;132A:130–135.
   PubMed Web of Science ®Google Scholar
• Wasniewska M, Corrias A, Salerno M, et al. Thyroid function patterns at Hashimoto’s thyroiditis presentation in childhood and adolescence are mainly conditioned by patients’ age. Horm Res Paediatr. 2012;78:232–236.
   PubMed Web of Science ®Google Scholar
• Nabhan ZM, Kreher NC, Eugster EA. Hashitoxicosis in children: clinical features and natural history. J Pediatr. 2005;146:533–536.
   PubMed Web of Science ®Google Scholar
• Wasniewska M, Corrias A, Salerno M, et al. Outcomes of children with Hashitoxicosis. Horm Res Paediatr. 2012;77:36–40.
   PubMed Web of Science ®Google Scholar
• Aversa T, Valenzise M, Corrias A, et al. Subclinical hyperthyroidism when presenting as initial manifestation of juvenile Hashimoto’s thyroiditis: first report on its natural history. J Endocrinol Invest. 2014;37:303–308.
   PubMed Web of Science ®Google Scholar
• Tessaris D, Corrias A, Matarazzo P, et al. Thyroid abnormalities in children and adolescents with McCune-Albright syndrome. Horm Res Paediatr. 2012;78:151–157.
   PubMed Web of Science ®Google Scholar
• Léger J. Pediatric thyroid autoimmunity. Arch Pediatr. 2010;17:595–596.
   PubMed Web of Science ®Google Scholar
• Mastorakos G, Mitsiades NS, Doufas AG, et al. Hyperthyroidism in McCune-Albright syndrome with a review of thyroid abnormalities sixty years after the first report. Thyroid. 1997;7:433–439.
   PubMed Web of Science ®Google Scholar
• Sallum AC, Leonhardt FD, Cervantes O, et al. Hyperthyroidism related to McCune-Albright syndrome: report of two cases and review of the literature. Arq Bras Endocrinol Metabol. 2008;52:556–561.
   PubMed Web of Science ®Google Scholar
• Shenker A, Weinstein LS, Moran A, et al. Severe endocrine and nonendocrine manifestations of the McCune-Albright syndrome associated with activating mutations of stimulatory G protein GS. J Pediatr. 1993;123:509–518.
   PubMed Web of Science ®Google Scholar
• Collins MT, Sarlis NJ, Merino MJ, et al. Thyroid carcinoma in the McCune-Albright syndrome: contributory role of activating Gs alpha mutations. J Clin Endocrinol Metab. 2003;88:4413–4417.
   PubMed Web of Science ®Google Scholar
• Congedo V, Celi FS. Thyroid disease in patients with McCune-Albright syndrome. Pediatr Endocrinol Rev. 2007;4(Suppl 4):429–433.
   PubMedGoogle Scholar
• Niedziela M. Thyroid nodules. Best Pract Res Clin Endocrinol Metab. 2014;28:245–277.
   PubMed Web of Science ®Google Scholar
• Tfayli HM, Teot LA, Indyk JA, et al. Papillary thyroid carcinoma in an autonomous hyperfunctioning thyroid nodule: case report and review of the literature. Thyroid. 2010;20:1029–1032.
   PubMed Web of Science ®Google Scholar
• Damle N, Gupta S, Kumar P, et al. Papillary carcinoma masquerading as clinically toxic adenoma in very young children. J Pediatr Endocrinol Metab. 2011;24:1051–1054.
   PubMed Web of Science ®Google Scholar
• Ruggeri RM, Campennì A, Giovinazzo S, et al. Follicular variant of papillary thyroid carcinoma presenting as toxic nodule in an adolescent: coexistent polymorphism of the TSHR and Gsα genes. Thyroid. 2013;23:239–242.
   PubMed Web of Science ®Google Scholar
• Gabalec F, Svilias I, Plasilova I, et al. Follicular variant of papillary carcinoma presenting as a hyperfunctioning thyroid nodule. J Pediatr Hematol Oncol. 2014;36:e94–e96.
   PubMed Web of Science ®Google Scholar
• Bakker O. Resistance to thyroid hormone in childhood. In: Krassas GE, Rivkees SA, Kiess W, editors. Disease of the thyroid in childhood and adolescence. Pediatr Adolesc Med. Vol. 11. Basel: Karger; 2007. p. 142–153.
   Google Scholar
• Jackman S, Diamond F. Pituitary adenomas in childhood and adolescence. Pediatr Endocrinol Rev. 2013;10:450–459.
   PubMedGoogle Scholar
• Fliers E, Boelen A, van Trotsenburg AS. Central regulation of the hypothalamo-pituitary-thyroid (HPT) axis: focus on clinical aspects. Handb Clin Neurol. 2014;124:127–138.
   PubMedGoogle Scholar
• Cannavo S, Venturino M, Curto L, et al. Clinical presentation and outcome of pituitary adenomas in teenagers. Clin Endocrinol. 2003;58:519–527.
   PubMed Web of Science ®Google Scholar
• Lafranchi SH, Snyder DB, Sesser DE, et al. Follow-up of newborns with elevated screening T4 concentrations. J Pediatr. 2003;143:296–301.
   PubMed Web of Science ®Google Scholar
• Persani L, Campi I, Marelli F. Syndromes of resistance to thyroid hormone action. In: Bona G, De Luca F, Monzoni A, editors. Thyroid diseases in childhood: recent advances from basic science to clinical practice. Basel (Switzerland): Springer; 2015. p. 95–112.
   Google Scholar
• Brucker-Davis F, Skarulis MC, Grace MB, et al. Genetic and clinical features of 42 kindreds with resistance to thyroid hormone. The National Institutes of Health Prospective Study. Ann Intern Med. 1995;123:572–583.
   PubMed Web of Science ®Google Scholar
• Weiss RE, Refetoff S. Resistance to thyroid hormone. Rev Endocr Metab Disord. 2000;1:97–108.
   PubMedGoogle Scholar
• Beck-Peccoz P, Persani L, Mantovani S, et al. Thyrotropin-secreting pituitary adenomas. Metabolism. 1996;45(Suppl 1):75–79.
   PubMed Web of Science ®Google Scholar
• Weiss RE, Refetoff S. Treatment of resistance to thyroid hormone – primum non nocere. J Clin Endocrinol Metab. 1999;84:401–404.
   PubMed Web of Science ®Google Scholar
• Ueda S, Takamatsu J, Fukata S, et al. Differences in response of thyrotropin to 3,5,3ʹ-triiodothyronine and 3,5,3ʹ-triiodothyroacetic acid in patients with resistance to thyroid hormone. Thyroid. 1996;6:563–570.
   PubMed Web of Science ®Google Scholar
• Darendeliler F, Baş F. Successful therapy with 3,5,3ʹ-triiodothyroacetic acid (TRIAC) in pituitary resistance to thyroid hormone. J Pediatr Endocrinol Metab. 1997;10:535–538.
   PubMed Web of Science ®Google Scholar
• Radetti G, Persani L, Molinaro G, et al. Clinical and hormonal outcome after two years of triiodothyroacetic acid treatment in a child with thyroid hormone resistance. Thyroid. 1997;7:775–778.
   PubMed Web of Science ®Google Scholar
• Torre P, Bertoli M, Di Giovanni S, et al. Endocrine and neuropsychological assessment in a child with a novel mutation of thyroid hormone receptor: response to 12-month triiodothyroacetic acid (TRIAC) therapy. J Endocrinol Invest. 2005;28:657–662.
   PubMed Web of Science ®Google Scholar
• Weiss RE, Stein MA, Refetoff S. Behavioral effects of liothyronine (L-T3) in children with attention deficit hyperactivity disorder in the presence and absence of resistance to thyroid hormone. Thyroid. 1997;7:389–393.
   PubMed Web of Science ®Google Scholar
• Anselmo J, Cao D, Karrison T, et al. Fetal loss associated with excess thyroid hormone exposure. JAMA. 2004;292:691–695.
   PubMed Web of Science ®Google Scholar